Pfizer Corporation

Xiaoyuan Sherry Chi

Philip R Dormitzer

Ye Che

Xiaojie Yao

Yuhang Liu

Jennifer Anne Nicki

Xinzhen Yang

Thomas Richard Jones

Seungil Han

Xiayang Qiu

Matthew Curtis Griffor

Kyle Paul Heim

Polypeptides and cytomegalovirus (CMV) antigens that include at least two introduced amino acid mutations relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). For example, polypeptides stabilized in a conformation alternative to the gB postfusion conformation. Compositions including the polypeptides and uses thereof.

Human cytomegalovirus gB polypeptide

The present invention comprises mutants of a wild-type cytomegalovirus (CMV) glycoprotein B (gB) protein that include at least two introduced amino acid mutations relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB), compositions including the mutants and uses thereof. In some embodiments, the mutant is stabilized in a conformation alternative to the gB postfusion conformation.

Human cytomegalovirus GB polypeptide

The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least one introduced amino acid mutation relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). In some embodiments, the polypeptide is stabilized in a conformation alternative to the gB postfusion conformation. Also disclosed are compositions including the polypeptides and uses thereof.

The present invention relates to a polypeptide that includes at least one mutation in the fusion loop 1 region and/or in the fusion loop 2 region and/or in the furin-like cleavage site of a human cytomegalovirus gB polypeptide. In one embodiment, the polypeptide undergoes a structural conformation change in response to pH change.

Growing community of inventors

Tenafly, NJ, United States of America

Xiaoyuan Sherry Chi